TW202423948A - 環狀胜肽衍生物與其製造方法以及組成物 - Google Patents

環狀胜肽衍生物與其製造方法以及組成物 Download PDF

Info

Publication number
TW202423948A
TW202423948A TW112129422A TW112129422A TW202423948A TW 202423948 A TW202423948 A TW 202423948A TW 112129422 A TW112129422 A TW 112129422A TW 112129422 A TW112129422 A TW 112129422A TW 202423948 A TW202423948 A TW 202423948A
Authority
TW
Taiwan
Prior art keywords
group
compound
hydrogen atom
mmol
solution
Prior art date
Application number
TW112129422A
Other languages
English (en)
Chinese (zh)
Inventor
松本恒平
苅田祐馬
安井航佑
田部七大
正司武嗣
Original Assignee
日商第一工業製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商第一工業製藥股份有限公司 filed Critical 日商第一工業製藥股份有限公司
Publication of TW202423948A publication Critical patent/TW202423948A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW112129422A 2022-08-04 2023-08-04 環狀胜肽衍生物與其製造方法以及組成物 TW202423948A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2022-124810 2022-08-04
JP2022124810 2022-08-04
JP2022159060 2022-09-30
JP2022-159060 2022-09-30

Publications (1)

Publication Number Publication Date
TW202423948A true TW202423948A (zh) 2024-06-16

Family

ID=89849507

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112129422A TW202423948A (zh) 2022-08-04 2023-08-04 環狀胜肽衍生物與其製造方法以及組成物

Country Status (12)

Country Link
US (1) US20260035407A1 (https=)
EP (1) EP4567042A1 (https=)
JP (1) JPWO2024029630A1 (https=)
KR (1) KR20250044905A (https=)
CN (1) CN119731193A (https=)
AU (1) AU2023317392A1 (https=)
CO (1) CO2025001948A2 (https=)
IL (1) IL318676A (https=)
MX (1) MX2025001373A (https=)
PE (1) PE20250797A1 (https=)
TW (1) TW202423948A (https=)
WO (1) WO2024029630A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2016047638A1 (ja) * 2014-09-24 2016-03-31 国立大学法人岩手大学 環状ペプチド誘導体とその製造方法および組成物
JP7486328B2 (ja) * 2020-03-05 2024-05-17 株式会社バイオコクーン研究所 神経突起伸長促進剤、神経細胞の樹状突起発現促進剤、及び神経栄養因子様作用物質
JP7695662B2 (ja) * 2020-11-02 2025-06-19 公立大学法人大阪 環状ペプチド誘導体の製造方法及び環状ペプチド化合物の製造方法

Also Published As

Publication number Publication date
MX2025001373A (es) 2025-03-07
CN119731193A (zh) 2025-03-28
JPWO2024029630A1 (https=) 2024-02-08
IL318676A (en) 2025-03-01
KR20250044905A (ko) 2025-04-01
PE20250797A1 (es) 2025-03-14
AU2023317392A9 (en) 2026-02-12
US20260035407A1 (en) 2026-02-05
WO2024029630A1 (ja) 2024-02-08
CO2025001948A2 (es) 2025-03-06
EP4567042A1 (en) 2025-06-11
AU2023317392A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
JP7811578B2 (ja) 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
CN102459185B (zh) 新型甲状腺激素β受体激动剂
CN108290878B (zh) 新的膜铁转运蛋白抑制剂
JP4024309B2 (ja) 新規な感染症治療薬
TWI471322B (zh) 新穎醯胺衍生物及其作為醫藥之用途
JPWO1998017625A1 (ja) 新規な感染症治療薬
CN111295372B (zh) 硝羟喹啉前药及其用途
JPWO2005108370A1 (ja) ベンゼン化合物
JP2018507903A (ja) ブロモドメイン阻害剤としてのベンゾイミダゾール誘導体
CN111135171A (zh) 与毒性醛相关的疾病和治疗
TW201706275A (zh) 具有ｈｉｖ複製抑制作用之含氮３環性衍生物
CN115867545A (zh) 抗病毒素1,3-二氧代茚化合物
WO1994010157A1 (fr) Derive du styrene et sels de ce derive
TW202525320A (zh) 用於處置或預防中樞神經系損傷疾病的環狀胜肽衍生物組成物
CN101981012A (zh) 新的四氢异喹啉衍生物
CN113874375A (zh) 用于治疗狂犬病的环状酰胺化合物及其方法
CN116283918A (zh) 一种降解受体酪氨酸激酶的双功能化合物及其应用
TW202423948A (zh) 環狀胜肽衍生物與其製造方法以及組成物
WO2025067477A1 (zh) 抗鲍曼不动杆菌的环肽及其应用
TW202506167A (zh) 用以處置或預防神經障礙性疼痛及／或炎症性疼痛的環狀胜肽衍生物組成物
HK40122917A (zh) 环状肽衍生物及其制造方法和组合物
HK40128045A (zh) 用於处置或预防中枢神经系统损伤疾病的环状肽衍生物组合物
TW202547546A (zh) 用以改善腦功能之環狀肽衍生物組成物
TW202545557A (zh) 用以調節睪固酮之產生／分泌的環狀肽衍生物組成物
HK40129190A (zh) 用於处置或预防神经病理性疼痛和/或炎性疼痛的环状肽衍生物组合物